目的 探讨检测超敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）、降钙素原（PCT）对新型冠状病毒肺炎（COVID-19）患者预后评估的临床价值。方法 选择150例COVID-19患者按诊断标准分为4组：轻型组（48例）、普通型组（45例）、重型组（35例）、危重型组（22例），测定各组患者血清hs-CRP、IL-6、PCT水平，并分析血清hs-CRP、IL-6、PCT水平对COVID-19患者预后评估以及对死亡风险的预测。结果 对于血清hs-CRP、IL-6、PCT水平，危重型组 > 重型组 > 普通型组 > 轻型组，差异均有统计学意义（P<0.05）。随着患者病情的加重，APACHE II评分也逐渐升高，但差异无统计学意义。血清hs-CRP、IL-6、PCT三者联合检测对患者预后的判断强于单一项目。与存活组比较，死亡组的hs-CRP、IL-6、PCT明显升高，两组比较差异具有统计学意义（P<0.05）。血清hs-CRP、IL-6、PCT水平联合检测在预测COVID-19死亡风险的准确率大于单一项目（P<0.05），与APACHE II评分相差不大。结论 血清hs-CRP、IL-6、PCT联合检测有助于判断COVID-19患者的预后，并且可以用来评估COVID-19患者的死亡风险。

Objective To explore the clinical value of detecting hs-CRP, interleukin 6(IL-6) and procalcitonin (PCT) in evaluating the prognosis of patients with COVID-19. Methods Patients (150 cases) with COVID-19 were divided into four groups according to diagnostic criteria:mild group (48 cases), normal group (45 cases), serious group (35 cases), and critical group (22 cases). The serum levels of hs-CRP, IL-6, and PCT were measured, serum levels of hs-CRP, IL-6, and PCT were analyzed to assess the prognosis of COVID-19 and to predict the risk of death. Results For the levels of hs-CRP, IL-6, and PCT, the critical group > serious group > normal group > mild group, with significant difference (P<0.05). APACHE II score increased with the progression of COVID-19, but there was no significant difference. The combined detection of hs-CRP, IL-6, and PCT was more effective than the single item in predicting the prognosis of patients. Compared with the survival group, hs-CRP, IL-6, and PCT in death group were significantly increased (P<0.05). The accuracy in predicting the risk of death from COVID-19 of the combined detection of hs-CRP, IL-6, and PCT was more than the detection of single item (P<0.05), and similar to that of APACHE II. Conclusion The combination of serum hs-CRP, IL-6, and PCT can be used to predict the prognosis of patients with COVID-19 and to assess the risk of death in patients with COVID-19.

R927.1